FAH and tyrosinemia: To investigate the effect of the inhibitors (G2-compounds and G1.30.B10) in the tyrosinemia catabolism, we employed CRISPR/Cas9 technology to transform HEK293 cells into human cellular models of HT1 by replacing the endogenous FAH WT by means of the generation of the carrying G337S (Figure 4A).